Root Cause: Why does Regulatory Approval Not Always Equate to Commercial Success?
Why is it that some approved products do not have commercial success and market adoption? There are in my opinion three major reasons; 1) Addressable market based on the product label; 2) Product manufacturability, 3) The pricing power versus the cost. What is at the denominator for all three major reasons for commercial failure?
The root cause is a regulatory strategy that early on fails to define the most critical aspect of product development which is the Target Product Profile (TPP). The TPP is defined in many ways but it essentially involves deciding what the manufacturers have to do clinically to assess the safety and efficacy of their product based on the proposed Mechanism of Action (MOA) and other product attributes. The TPP eventually defines the final drug product label. In reality, what is claimed on the product label is not only a reflection of the product characteristics and MOA but it is also about other factors (see below).
So what should a manufacturer consider in their regulatory strategy to address this root cause? They should consider addressing the four major factors that are directly or indirectly linked to the product TPP; and what is ultimately approved on the final drug product label.
-
Addressable market based on approved product label: The product label defines the addressable market not vice versa.
-
Manufacturability: The manufacturers tend to forget that if you cannot make the product consistently at the cost that is affordable to payers, as defined by the labeling claim, the commercial success of a product could be at jeopardy!
-
Pricing: The pricing power is often determined by the manufacturing cost and what the market can tolerate based on the label of the final drug product and any competing therapies.
- Intellectual Property (IP): The IP consideration may be very difficult to assess early on but a weak initial IP position will ultimately and definitely be expected to increase the cost of the approved product.
The manufacturers often view an optimal regulatory strategy as one that permits them getting access to the market the fastest way but this approach could potentially be short sighted! The real solution to these challenges lies in conducting a careful regulatory strategy analysis, very early on, that encompasses not only the regulatory and technical considerations, but it also includes various considerations as outlined above. For this reason, Parexel has chosen to provide their client’s with an integrated approach for regulatory strategy that considers not only the technology and product attributes, and non-clinical and clinical considerations, but also other factors such as the addressable market based on the final approved labeling, IP considerations, and competing market analysis.
In the end a successful strategy must be commercially sustainable one that requires consideration of some of these aforementioned factors in a sequential manner allowing for commercial, business and marketing assumptions which are based on the best scientific and regulatory analyses.
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023